Payment overview · 2025
General Payments
$312.88
17 reported records · 12 companies
Healthcare provider profile · identity verified
Claudia Vera, MD
Allopathic & Osteopathic Physicians|Internal Medicine · ROMEOVILLE, IL · NPI 1811966534
Verified facts
What the public records show
CMS Open Payments records show Claudia Vera, MD received $312.88 in general payments during 2025 across 17 reported records.
Amgen Inc. accounted for 20.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Linzess.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Myrbetriq by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Jardiance by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $64.27 | 20.5% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $39.33 | 12.6% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $34.11 | 10.9% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $25.18 | 8.1% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $24.06 | 7.7% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $23.77 | 7.6% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $23.35 | 7.5% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.55 | 6.2% | 2 | 2025 |
| Exeltis, USA Inc. | Unresolved — no canonical attribution shown | $16.69 | 5.3% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $14.85 | 4.8% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $14.11 | 4.5% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $13.61 | 4.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $312.88 | 17 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $43.07 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $43.07 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $34.11 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $25.18 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $25.18 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $24.06 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $23.77 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $23.77 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $23.35 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $21.20 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $20.41 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $19.55 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $18.92 | 1 | 2025 |
Source payment records
|
|||||
| SLYND Normalized: slynd |
Drug | Exeltis, USA Inc. | $16.69 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $14.85 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $14.85 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $14.11 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $13.61 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| LINZESS linzess |
2025 | Linzess | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
60 | 21 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
60 | 19 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
14 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 537 | 173 |
| Levothyroxine Sodium | Levothyroxine Sodium | 364 | 111 |
| Losartan Potassium | Losartan Potassium | 318 | 106 |
| Amlodipine Besylate | Amlodipine Besylate | 310 | 104 |
| Metformin Hcl | Metformin Hcl | 296 | 105 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 255 | 92 |
| Lisinopril | Lisinopril | 234 | 68 |
| Omeprazole | Omeprazole | 232 | 77 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 204 | 88 |
| Pioglitazone Hcl | Pioglitazone Hcl | 195 | 67 |
| Tamsulosin Hcl | Tamsulosin Hcl | 191 | 66 |
| Alendronate Sodium | Alendronate Sodium | 161 | 54 |
| Alprazolam | Alprazolam | 159 | 41 |
| Gabapentin | Gabapentin | 145 | 52 |
| Hydrochlorothiazide | Hydrochlorothiazide | 144 | 59 |
| Meloxicam | Meloxicam | 140 | 56 |
| Pantoprazole Sodium | Pantoprazole Sodium | 125 | 49 |
| Pravastatin Sodium | Pravastatin Sodium | 124 | 37 |
| Trazodone Hcl | Trazodone Hcl | 122 | 44 |
| Simvastatin | Simvastatin | 113 | 28 |
| Glimepiride | Glimepiride | 105 | 33 |
| Metformin Hcl Er | Metformin Hcl | 101 | 42 |
| Metoprolol Succinate | Metoprolol Succinate | 100 | 32 |
| Tramadol Hcl | Tramadol Hcl | 99 | 26 |
| Fluticasone Propionate | Fluticasone Propionate | 93 | 42 |
| Escitalopram Oxalate | Escitalopram Oxalate | 92 | 31 |
| Carvedilol | Carvedilol | 91 | 31 |
| Tizanidine Hcl | Tizanidine Hcl | 89 | 23 |
| Montelukast Sodium | Montelukast Sodium | 86 | 25 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 84 | 46 |
| Furosemide | Furosemide | 81 | 30 |
| Meclizine Hcl | Meclizine Hcl | 81 | 28 |
| Potassium Chloride | Potassium Chloride | 81 | 24 |
| Allopurinol | Allopurinol | 74 | 18 |
| Sertraline Hcl | Sertraline Hcl | 74 | 23 |
| Metoprolol Tartrate | Metoprolol Tartrate | 67 | 23 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 66 | 29 |
| Ozempic | Semaglutide | 64 | 17 |
| Vascepa | Icosapent Ethyl | 62 | 14 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 61 | 39 |
| Eliquis | Apixaban | 60 | 19 |
| Jardiance | Empagliflozin | 60 | 21 |
| Azelastine Hcl | Azelastine Hcl | 55 | 30 |
| Finasteride | Finasteride | 54 | 17 |
| Lorazepam | Lorazepam | 53 | 11 |
| Famotidine | Famotidine | 52 | 15 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 51 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 50 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 50 | 15 |
| Glipizide Er | Glipizide | 49 | 15 |
| Torsemide | Torsemide | 48 | 11 |
| Azithromycin | Azithromycin | 46 | 38 |
| Cephalexin | Cephalexin | 45 | 37 |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 45 | 13 |
| Januvia | Sitagliptin Phosphate | 45 | 15 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 44 | 18 |
| Valsartan | Valsartan | 44 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 43 | 13 |
| Farxiga | Dapagliflozin Propanediol | 43 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 43 | 32 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 42 | 11 |
| Chlorthalidone | Chlorthalidone | 41 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 38 | 29 |
| Ondansetron Hcl | Ondansetron Hcl | 38 | 20 |
| Clopidogrel | Clopidogrel Bisulfate | 37 | 15 |
| Glipizide | Glipizide | 36 | suppressed |
| Ketoconazole | Ketoconazole | 36 | 15 |
| Nifedipine Er | Nifedipine | 36 | 11 |
| Pregabalin | Pregabalin | 34 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 34 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 33 | 12 |
| Atenolol | Atenolol | 33 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 33 | suppressed |
| Fluconazole | Fluconazole | 33 | 20 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 33 | 15 |
| Ezetimibe | Ezetimibe | 32 | 12 |
| Sucralfate | Sucralfate | 32 | 14 |
| Diazepam | Diazepam | 31 | suppressed |
| Memantine Hcl | Memantine Hcl | 31 | suppressed |
| Terconazole | Terconazole | 30 | 17 |
| Telmisartan | Telmisartan | 29 | suppressed |
| Baclofen | Baclofen | 28 | suppressed |
| Methylprednisolone | Methylprednisolone | 28 | 21 |
| Procto-Med Hc | Hydrocortisone | 27 | suppressed |
| Nystatin | Nystatin | 26 | 11 |
| Bupropion Xl | Bupropion Hcl | 24 | suppressed |
| Calcitriol | Calcitriol | 24 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 24 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 24 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 23 | 11 |
| Ibuprofen | Ibuprofen | 23 | suppressed |
| Myrbetriq | Mirabegron | 23 | suppressed |
| Naproxen | Naproxen | 23 | suppressed |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 23 | 18 |
| Temazepam | Temazepam | 23 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 22 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 22 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 21 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 21 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 21 | suppressed |
| Spironolactone | Spironolactone | 21 | suppressed |
| Celecoxib | Celecoxib | 20 | 11 |
| Dicyclomine Hcl | Dicyclomine Hcl | 20 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 20 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 20 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 20 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 19 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 19 | 18 |
| Levetiracetam | Levetiracetam | 19 | suppressed |
| Lidocaine | Lidocaine | 19 | suppressed |
| Lovastatin | Lovastatin | 19 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 18 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 18 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 18 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 17 | suppressed |
| Ciclopirox | Ciclopirox | 17 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 16 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 16 | suppressed |
| Mirtazapine | Mirtazapine | 16 | suppressed |
| Synthroid | Levothyroxine Sodium | 16 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 16 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 15 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 14 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Linzess | Linaclotide | 14 | suppressed |
| Novolog Flexpen | Insulin Aspart | 14 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 14 |
| Trintellix | Vortioxetine Hydrobromide | 14 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Clonazepam | Clonazepam | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Hydrocortisone | Hydrocortisone | 13 | suppressed |
| Mupirocin | Mupirocin | 13 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 13 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 12 | suppressed |
| Prednisone | Prednisone | 12 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 11 | suppressed |
| Irbesartan | Irbesartan | 11 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 11 | suppressed |
| Trueplus Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 11 | suppressed |
| Xarelto | Rivaroxaban | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $312.88 · 17 records | Amgen Inc. | AREXVY, CREON, Cologuard Collection Kit, EVENITY, GEMTESA, INSPIRE, LINZESS, MOUNJARO, NURTEC ODT, OTEZLA, REPATHA, SHINGRIX, SLYND, The Cologuard Plus Collection Kit, VOQUEZNA, Veozah, ZAVZPRET, ZORYVE | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Linzess play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error